APA (7th ed.) Citation

Suvannasankha, A., Kaiser, M., Lee, D., Dlotko, E., Macleod, P., Boytsov, N., . . . McNamara, S. (2025). EE327 Belantamab Mafodotin, Pomalidomide, and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): Quality-Adjusted Life-Year (QALY) Results From a Cost-Effectiveness Model. Value in Health, 28(6), S122. https://doi.org/10.1016/j.jval.2025.04.1926

Chicago Style (17th ed.) Citation

Suvannasankha, Attaya, et al. "EE327 Belantamab Mafodotin, Pomalidomide, and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): Quality-Adjusted Life-Year (QALY) Results From a Cost-Effectiveness Model." Value in Health 28, no. 6 (2025): S122. https://doi.org/10.1016/j.jval.2025.04.1926.

MLA (9th ed.) Citation

Suvannasankha, Attaya, et al. "EE327 Belantamab Mafodotin, Pomalidomide, and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): Quality-Adjusted Life-Year (QALY) Results From a Cost-Effectiveness Model." Value in Health, vol. 28, no. 6, 2025, p. S122, https://doi.org/10.1016/j.jval.2025.04.1926.